Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

Yohann Loriot,Thomas Powles,Miguel Ángel Climent Duran,Srikala S. Sridhar,Joaquim Bellmunt,Daniel P. Petrylak,Jing Wang,Nuno Matos Costa,Robert J Laliberte,Alessandra di Pietro,Petros Grivas,Cora N. Sternberg

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

2021

Yohann Loriot
Thomas Powles
Miguel Ángel Climent Duran
Srikala S. Sridhar
Joaquim Bellmunt
Daniel P. Petrylak
Jing Wang
Nuno Matos Costa
Robert J Laliberte
Alessandra di Pietro
Petros Grivas
Cora N. Sternberg

438Background: Avelumab 1L maintenance is approved in the United States for patients with advanced UC that has not progressed with 1L platinum-containing chemotherapy based on significantly prolong...

Keywords:

Avelumab
Oncology
Subgroup analysis
Javelin
urothelial carcinoma
first line
Chemotherapy
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations